Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.34 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.34 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonidine SCHEMBL5982 | 1.00 | MAPT (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL3974275 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL1172959 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL10972183 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL22127030 | 0.98 | MAPT (0.35) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL40751 | 0.98 | ADRA2A (0.36) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL9838987 | 0.98 | MAPT (0.35) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL22127029 | 0.96 | MAPT (0.34) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL1369066 | 0.96 | MAPT (0.34) | MAPTHSP90AA1ADRA2AADRA2CADRA1D | |
| Clonidine SCHEMBL27404261 | 0.94 | MAPT (0.37) | MAPTHSP90AA1ADRA2AADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10998091-B2 | Systems for monitoring compliance with a patch dosage regimen and methods of using the same | PATIL SANDEEP (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200258610-A1 | Systems for Monitoring Compliance with a Patch Dosage Regimen and Methods of Using the Same | PATIL SANDEEP (US) | 2020-08-13 | — | — | US | disclosed |
| US-20180221297-A1 | System and Method for Improving Adhesion of Transdermal Delivery Devices | CHARTWELL TRANSDERMALS, LLC | 2018-08-09 | — | — | US | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| EP-2395997-B1 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS. | ONXEO S A (FR) | 2016-02-10 | — | — | EP | disclosed |
| US-9192599-B2 | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers | ONXEO S.A. (FR) | 2015-11-24 | — | — | US | disclosed |
| WO-2015165948-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | PHARNEXT (FR) | 2015-11-05 | — | — | WO | disclosed |
| US-9089559-B2 | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers | ONXEO S.A. (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20150148398-A1 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS | Monopar Therapeutics Inc. | 2015-05-28 | — | — | US | disclosed |
| US-20130274306-A1 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS | Monopar Therapeutics Inc. | 2013-10-17 | — | — | US | disclosed |
| US-20110288140-A1 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS | BIOALLIANCE PHARMA ,S.A. (FR) | 2011-11-24 | — | — | US | disclosed |
| CN-101842081-A | Compositions and methods comprising clonidine for treating post-operative pain | WARSAW ORTHOPEDIC INC | 2010-09-22 | — | — | CN | disclosed |
| WO-2010031819-A1 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS. | BIOALLIANCE PHARMA (FR) | 2010-03-25 | — | — | WO | disclosed |
| EP-1689401-A1 | METHOD FOR REDUCING PAIN | Elan Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005112911-A2 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005032556-A1 | METHOD FOR REDUCING PAIN | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-1999063997-A1 | USE OF CLONIDINE FOR TREATMENT OF ADDICTIONS, EPILEPSY, SLEEP DISORDERS, EATING DISORDERS AND MIGRAINES | JANOV ARTHUR (FR) | 1999-12-16 | — | — | WO | disclosed |
| US-5175052-A | Porous polytetrafluoroethylene sheet coated with pressure-sensitive adhesive terpolymer of 2-ethylhexyl acrylate, 2-methoxyethyl acrylate and vinyl acetate, for sustained release drug delivery | NITTO DENKO CORPORATION (JP) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10998091-B2 | Systems for monitoring compliance with a patch dosage regimen and methods of using the same | CUTA, ACHE, PTPN21 | ADRA2A 2715/4885ADRA2C 2414/4885ADRA2B 4061/4885 |
| US-20200258610-A1 | Systems for Monitoring Compliance with a Patch Dosage Regimen and Methods of Using the Same | CUTA, ACHE, PTPN21 | ADRA2A 2715/4885ADRA2C 2414/4885ADRA2B 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.